
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio is expected to experience financial growth with the potential approval of Jemperli for colorectal cancer and their partnership with Tesaro and GSK. However, a legal dispute with GSK may impact their development and commercialization plans for Jemperli. The company's other drug, imsidolimab, is also in development and expected to contribute to financial growth. Overall, AnaptysBio appears to be in a strong financial position and has potential for success in the pharmaceutical industry.
Bears say
AnaptysBio is a biotechnology company that has seen impressive growth with its rheumatoid arthritis drug, Jemperli, but there are multiple risks in the biotechnology sector including clinical, regulatory, and commercial risks, as well as a need for significant capital. Furthermore, there is an ongoing dispute with GSK/Tesaro over royalties for Jemperli, leading to potential delays in approval and uptake for the drug. The company also has a potential revenue inflection point with its other drug, imsidolimab, but ongoing litigation and regulatory risks could impede future growth.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares